Akebia Therapeutics (AKBA) Accounts Payables (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Accounts Payables data on file, last reported at $8.4 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 33.75% year-over-year to $8.4 million in Q1 2026; TTM through Mar 2026 was $8.4 million, a 33.75% decrease from a year earlier, with the FY2025 full-year figure at $21.2 million, up 39.56% from the prior year.
• Accounts Payables for Q1 2026 stood at $8.4 million, down from $21.2 million in the prior quarter.
• Over the last five years, Accounts Payables for AKBA reached as high as $24.9 million in Q2 2022 and fell as low as $8.4 million in Q1 2026.
• Historically, Accounts Payables has averaged $14.4 million across 5 years, with a median of $12.7 million in 2025.
• Across the five-year window, Accounts Payables sank 54.14% in 2023 and soared 49.3% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $18.0 million in 2022, then decreased by 18.79% to $14.6 million in 2023, then increased by 3.72% to $15.2 million in 2024, then surged by 39.56% to $21.2 million in 2025, then plunged by 60.42% to $8.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $8.4 million in Q1 2026, $21.2 million in Q4 2025, and $10.1 million in Q3 2025.